KDR and nasopharyngeal carcinoma: There are ongoing clinical trials propose the combination of PD-1/PD-L1 blockade with other immune checkpoint inhibitors such as anti-CTLA-4 or anti-angiogenic agents such as anti-VEGFR inhibitors as recommended therapeutic approach for NPC [408, 409].